Market Overview

Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to a Class Action


Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of Antares Pharma, Inc.
(NasdaqCM: ATRS) have filed a class action complaint against the
company's officers and directors for alleged violations of the
Securities Exchange Act of 1934 between December 21, 2016 and October
12, 2017. Antares, a specialty pharmaceutical company, develops
pharmaceutical delivery systems, including needle-free and mini-needle
injector systems and transdermal gel technologies. Antares' lead product
candidate is known as Xyosted.

View this information on the law firm's Shareholder Rights Blog:

Antares Accused of Overstating Approval Prospects for its Drug

According to the complaint, on December 21, 2016, Antares announced its
submission of a New Drug Application ("NDA") for Xyosted to the U.S.
Food and Drug Administration ("FDA") and spoke optimistically about the
drug's potential. However, Antares officials provided insufficient data
to the FDA for the NDA and overstated the approval prospects for
Xyosted. On October 12, 2017, Antares revealed that FDA had "identified
deficiencies that preclude the continuation of the discussion of
labeling and post marketing requirements/commitments" for Xyosted. On
this news, Antares' stock fell nearly 38% to close at $2.32 per share on
October 13, 2017. On October 20, 2017, Antares announced receipt of a
Complete Response Letter from the FDA stating that the FDA cannot
approve the NDA due to concerns about increase in blood pressure and the
occurrence of depression and suicidality.

Antares Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!